YD Bio Ltd
corporate_fare Company Profile
YD Bio Ltd (NASDAQ:YDES) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 8 items for YDES at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-31, rated 8/10. Across its 8 most recent items scored 7 or higher, the top rating is 8/10, with 5 rated 8 or above. Recent SEC coverage for YDES spans 424B3, 6-K.
Recent high-impact activity:
- YD Bio's H1 2026: Revenue Jumps 315%, but Going Concern Warning and Cash Burn Loom
- YD Bio Expands Cancer Detection Lab Reach to 46 States, Boosting Commercial Validation
- YD Bio Reports 12-Cent Loss Per Share for 2025
- YD Bio Forms Strategic Alliance with YC Biotech for Taiwan-U.S. Regulatory Platform
- YD Bio Ltd to Acquire Immunocell Therapy Firm SSMC for $26.87M, Bolstering Biotech Portfolio
Financial Snapshot
Short Interest & Short Volume
1.50 days to coverFINRA reported short interest of 187,405 shares in YDES as of the October 30, 2026 settlement, a 2.5% decrease from the prior period — about 1.5 days to cover at its recent average daily volume. On November 20, 2026, 61.9% of YDES volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
YDES files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.